Skip to content
10-Q

Quarterly Report

Foghorn Therapeutics Inc. FHTX

0001628280-26-031671

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 58.71M sh
Shares Diluted Q1 2026 · Mar 31, 2026 69.54M sh
Shares Diluted Q1 2026 · Mar 31, 2025 62.85M sh
Capex Q1 2026 · Mar 31, 2026 $0
Capex Q1 2026 · Mar 31, 2025 $28K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$25.27M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$23.97M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $87.66M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $80.88M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $61.03M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$76.41M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$108.5M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$61.65M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$45.53M
Current Liabilities Q1 2026 · Mar 31, 2026 $64.4M
Current Liabilities Q1 2026 · Dec 31, 2025 $59.74M
Total Liabilities Q1 2026 · Mar 31, 2026 $298.58M
Total Liabilities Q1 2026 · Dec 31, 2025 $306.6M
Current Assets Q1 2026 · Mar 31, 2026 $188.06M
Current Assets Q1 2026 · Dec 31, 2025 $163.24M
Total Assets Q1 2026 · Mar 31, 2026 $222.17M
Total Assets Q1 2026 · Dec 31, 2025 $198.1M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.29
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.30
Eps Basic Q1 2026 · Mar 31, 2026 −$0.29
Eps Basic Q1 2026 · Mar 31, 2025 −$0.30
Sga Expense Q1 2026 · Mar 31, 2026 $6.58M
Sga Expense Q1 2026 · Mar 31, 2025 $7.24M
Rd Expense Q1 2026 · Mar 31, 2026 $18.26M
Rd Expense Q1 2026 · Mar 31, 2025 $21.63M
Net Income Q1 2026 · Mar 31, 2026 −$19.88M
Net Income Q1 2026 · Mar 31, 2025 −$18.83M
Operating Income Q1 2026 · Mar 31, 2026 −$21.57M
Operating Income Q1 2026 · Mar 31, 2025 −$22.91M
Revenue Q1 2026 · Mar 31, 2026 $3.27M
Revenue Q1 2026 · Mar 31, 2025 $5.95M